Effective strategies for the management of pyoderma gangrenosum: A comprehensive review

Acta Dermato-Venereologica

Volumn 95, Issue 5, 2015, Pages 525-531

  Patel, Forum ^a   Fitzmaurice, Sarah ^a   Duong, Christopher ^a   He, Young ^a   Fergus, Jonathan ^a   Raychaudhuri, Siba P ^b   Shirakawa Garcia, Miki ^a   Maverakis, Emanual ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Adalimumab; Biologic; Infliximab; IVIG; Mycophenolate mofetil; Pyoderma gangrenosum

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BRODALUMAB; CERTOLIZUMAB PEGOL; CLOFAZIMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; GEVOKIZUMAB; IMMUNOGLOBULIN; INFLIXIMAB; IXEKIZUMAB; LAMIVUDINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE DIACETATE; UNINDEXED DRUG; USTEKINUMAB; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT;

ANAPHYLAXIS; ASEPTIC MENINGITIS; CELL MIGRATION; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MONOTHERAPY; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ADOLESCENT; ADULT; COMPARATIVE STUDY; DEBRIDEMENT; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; COMBINED MODALITY THERAPY; DEBRIDEMENT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; PYODERMA GANGRENOSUM; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84928166902     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2008     Document Type: Review

References (114)

1. Horvath R, Duffy P, McCormack JG. Necrotic ulceration of the skin and fascia. Clin Infect Dis 2003; 36: 869, 925-866.
2. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34: 395-409; quiz 410-392.
3. Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988; 18: 511-521.
4. Quimby SR, Gibson LE, Winkelmann RK. Superficial granulomatous pyoderma: clinicopathologic spectrum. Mayo Clin Proc 1989; 64: 37-43.
5. Dobson CM, Parslew RA, Evans S. Superficial granulomatous pyoderma treated with intravenous immunoglobulin. J Am Acad Dermatol 2003; 48: 456-460.
6. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-1548.
7. O'Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 1978; 114: 1061-1064.
8. Duguid CM, O'Loughlin S, Otridge B, Powell FC. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol 1993; 34: 17-22.
9. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol 2012; 42: 135-144.
10. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, Jr., White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79: 37-46.
11. Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Curr Probl Surg 2010; 47: 384-445.
12. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma (echthyma) gangrenosum - Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph 1930; 22: 655-680.
13. Perry HO, Brunsting LA. Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch Derm 1957; 75: 380-386.
14. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87: 281-293.
15. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-119.
16. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012; 132: 2166-2170.
17. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122.
18. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-933.
19. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
20. Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, et al. Effective strategies for the management of pyoderma gangrenosum. Adv Wound Care 2012; 1: 194-199.
21. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002; 347: 1412-1418.
22. Thomas RHM, Payne CMER, Black MM. Wegeners granulomatosis presenting as pyoderma gangrenosum. Clin Exp Dermatol 1982; 7: 523-527.
23. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009; 23: 1008-1017.
24. Powell FC, Schroeter AL, Su WPD, Perry HO. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol 1983; 119: 468-472.
25. Stolman LP, Rosenthal D, Yaworsky R, Horan F. Pyoderma gangrenosum and rheumatoid-arthritis. Arch Dermatol 1975; 111: 1020-1023.
26. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes - response to immunosuppressive Therapy. Br J Haematol 1995; 91: 403-408.
27. Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 1999; 40: 507-538.
28. Tay CH. Pyoderma-gangrenosum and leukemia. Arch Dermatol 1973; 108: 580-581.
29. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple-myeloma. Arch Dermatol 1991; 127: 69-74.
30. Mahood JM, Sneddon IB. Pyoderma gangrenosum complicating non-Hodgkins lymphoma. Br J Dermatol 1980; 102: 223-225.
31. Jaimes-Lopez N, Molina V, Arroyave JE, Vasquez LA, Ruiz AC, Castano R, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 2009; 3: 20-23.
32. Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma- gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991; 68: 441-443.
33. Thakur N, Sodani R, Chandra J, Singh V. Leukocyte adhesion defect type 1 presenting with recurrent pyoderma gangrenosum. Indian J Dermatol 2013; 58: 158.
34. Vahlquist A, Håkansson LD, Rönnblom L, Karawajczyk M, Fasth A, van Gijn ME, et al. Recurrent pyoderma gangrenosum and cystic acne associated with leucocyte adhesion deficiency due to novel mutations in ITGB2: successful treatment with infliximab and adalimumab. Acta Derm Venereol 2014 Jul 4. [Epub ahead of print].
35. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000; 80: 595-604.
36. Oka M. Pyoderma gangrenosum and interleukin 8. Br J Dermatol 2007; 157: 1279-1281.
37. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143: 728-732.
38. Saito S, Yasui K, Hosoda W, Ogawa M, Kobayashi N, Sakashita K, et al. CD30+ anaplastic large cell lymphoma complicated by pyoderma gangrenosum with increased levels of serum cytokines. Eur J Haematol 2006; 77: 251-254.
39. Kawakami T, Yamazaki M, Soma Y. Reduction of interleukin- 6, interleukin-8, and anti-phosphatidylserineprothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol 2009; 104: 2363-2364.
40. Bister V, Makitalo L, Jeskanen L, Saarialho-Kere U. Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol 2007; 34: 889-898.
41. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509.
42. Mittal S, Milner BJ, Vickers MA. Pyoderma gangrenosum as a cause of splenomegaly and association with a T-cell clone. Clin Lab Haematol 2005; 27: 402-404.
43. Brooklyn TN, Williams AM, Dunnill MG, Probert CS. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 2007; 157: 960-966.
44. Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986; 13: 323-330.
45. Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun 2011; 37: 71-78.
46. Maverakis E, van den Elzen P, Sercarz EE. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts - from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 2001; 16.
47. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003; 3: 621-629.
48. Sercarz EE, Maverakis E. Recognition and function in a degenerate immune system. Mol Immunol 2004; 40: 1003-1008.
49. van den Elzen P, Menezes JS, Ametani A, Maverakis E, Madakamutil L, Tang XL, et al. Limited clonality in autoimmunity: drivers and regulators. Autoimmun Rev 2004; 3: 524-529.
50. Menezes JS, van den Elzen P, Thornes J, Huffman D, Droin NM, Maverakis E, et al. A public T cell clonotype within a heterogeneous autoreactive repertoire is dominant in driving EAE. J Clin Invest 2007; 117: 2176-2185.
51. Maverakis E. Sercarzian immunology - In memoriam. Eli E. Sercarz, 1934-2009. Cell Immunol 2012; 273: 99-108.
52. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-1201.
53. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocytederived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694-1697.
54. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J Autoimmun 2010; 34: J247-257.
55. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11: 961-969.
56. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100: 13501-13506.
57. Craig FF, Thomas KS, Mitchell EJ, Williams HC, Norrie J, Mason JM, et al. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 2012; 13: 51.
58. Richter-Hintz D, Schuppe HC, Homey B, Lehmann P, Ruzicka T. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 2000; 42: 304-304.
59. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 351: 832-832.
60. Moschell S. Pyoderma gangrenosum - a patient successfully treated with intralesional injections of steroid. Arch Dermatol 1967; 95: 121-123.
61. Jennings JL. Pyoderma gangrenosum - successful treatment with intralesional steroids. J Am Acad Dermatol 1983; 9: 575-580.
62. Mrowietz U, Christophers E. Clearing of pyodermagangrenosum by intralesional cyclosporine-A. Br J Dermatol 1991; 125: 499-499.
63. Faulds D, Goa KL, Benfield P. Cyclosporine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
64. Johnson RB, Lazarus GS. Pulse Therapy - Therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982; 118: 76-84.
65. Michaelsson G, Molin L, Öhman S, Gip L, Lindstrom B, Skogh M, et al. Clofazimine - new agent for treatment of pyoderma gangrenosum. Arch Dermatol 1976; 112: 344-349.
66. Curley RK, Macfarlane AW, Vickers CFH. Pyoderma gangrenosum treated with cyclosporin-A. Br J Dermatol 1985; 113: 601-604.
67. Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978; 21: 535-538.
68. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma-gangrenosum. J Am Acad Dermatol 1995; 32: 140-142.
69. Thomsen K, Rothenborg HW. Clofazimine in the treatment of pyoderma gangrenosum. Arch Dermatol 1979; 115: 851-852.
70. Hohenleutner U, Mohr VD, Michel S, Landthaler M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet 1997; 350: 1748-1748.
71. Crawford SE, Sherman R, Favara B. Pyoderma gangrenosum with response to cyclophosphamide therapy. J Pediatr 1967; 71: 255-258.
72. Venencie PY, Saurat JH. Pyoderma Gangrenosum in a child - treatment with thalidomide. Ann Pediatr 1982; 29: 67-69.
73. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134: 1509-1511.
74. Galun E, Flugelman MY, Rachmilewitz D. Pyodermagangrenosum complicating ulcerative-colitis - successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81: 988-989.
75. Happle R, Schiffer HP, Kovary PM. Ocular involvement in pyoderma gangrenosum. Arch Dermatol 1977; 113: 1612.
76. Medeiros CC, Colombari ML, Nassif PW, Gurgel AC, Nassif AE. [Pyoderma gangrenosum in an infant: Case report]. Dermatol Online J 2012; 18: 6 (Article in Portuguese).
77. Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996; 57: 326-328.
78. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996; 57: 315-319.
79. Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflammatory bowel diseases 2004; 10: 421-424.
80. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5: 763-773.
81. Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128: 1060-1064.
82. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 2013; 44: 121-140.
83. Roy DB, Conte ET, Cohen D. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 2006; 54: S128-S134.
84. Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNF alpha drug - Etanercept. J Plast Reconstr Aes 2008; 61: 431-433.
85. Pastor N, Betlloch I, Pascual JC, Blanes M, Banuls J, Silvestre JF. Pyoderma gangrenosum treated with anti- TNF alpha therapy (etanercept). Clin Exp Dermatol 2006; 31: 152-153.
86. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 2005; 16: 347-349.
87. Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. Jcr-J Clin Rheumatol 2004; 10: 50-52.
88. Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007; 46: 1095-1099.
89. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005; 152: 1059-1061.
90. Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5: e8.
91. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007; 157: 1274-1275.
92. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol 2007; 143: 306-308.
93. Jacob SE, Weisman RS, Kerdel FA. Pyoderma gangrenosum - rebel without a cure? Int J Dermatol 2008; 47: 192-194.
94. Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol 2009; 15: 2293-2295.
95. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
96. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194: 519-527.
97. Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147: 1203-1205.
98. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012; 107: 794-795.
99. Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92: 320-321.
100. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13: 1024-1030.
101. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158.
102. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895.
103. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
104. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851-864.
105. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
106. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192-2201.
107. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
108. Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 2007; 157: 1235-1239.
109. Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001; 12: 19-22.
110. Kreuter A, Reich-Schupke S, Stucker M, Altmeyer P, Gambichler T. Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol 2008; 158: 856-857.
111. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438-445.
112. Rozin A, Balbir-Gurman A, Gilead L, Slodownik D. Combined therapy for pyoderma gangrenosum. Ann Rheum Dis 2004; 63: 888-889.
113. Gilmour E, Stewart D. Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol 2001; 144: 397-400.
114. Hawryluk EB, Penn SK, Wasko MC, Johnson JT, Ferris LK. Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid. Ear Nose Throat J 2010; 89: E5-7.